MX2024000986A - Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. - Google Patents
Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.Info
- Publication number
- MX2024000986A MX2024000986A MX2024000986A MX2024000986A MX2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- treatment
- coronaviral
- related diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 101800000535 3C-like proteinase Proteins 0.000 abstract 2
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224793P | 2021-07-22 | 2021-07-22 | |
| US202163289009P | 2021-12-13 | 2021-12-13 | |
| PCT/IB2022/056712 WO2023002409A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000986A true MX2024000986A (es) | 2024-02-12 |
Family
ID=82742919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000986A MX2024000986A (es) | 2021-07-22 | 2022-07-20 | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092016A1 (https=) |
| EP (1) | EP4373814A1 (https=) |
| JP (1) | JP2024527424A (https=) |
| KR (1) | KR20240038996A (https=) |
| AU (1) | AU2022315058A1 (https=) |
| CA (1) | CA3226758A1 (https=) |
| MX (1) | MX2024000986A (https=) |
| PY (1) | PY2261702A (https=) |
| TW (1) | TW202321210A (https=) |
| UY (1) | UY39863A (https=) |
| WO (1) | WO2023002409A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| JP7624093B2 (ja) | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| WO2025125695A2 (en) * | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1200825B (de) * | 1962-01-13 | 1965-09-16 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen |
| WO2010149755A1 (en) * | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
-
2022
- 2022-07-19 UY UY0001039863A patent/UY39863A/es unknown
- 2022-07-19 TW TW111127023A patent/TW202321210A/zh unknown
- 2022-07-19 PY PY202202261702A patent/PY2261702A/es unknown
- 2022-07-20 CA CA3226758A patent/CA3226758A1/en active Pending
- 2022-07-20 EP EP22748094.4A patent/EP4373814A1/en active Pending
- 2022-07-20 MX MX2024000986A patent/MX2024000986A/es unknown
- 2022-07-20 WO PCT/IB2022/056712 patent/WO2023002409A1/en not_active Ceased
- 2022-07-20 KR KR1020247005669A patent/KR20240038996A/ko active Pending
- 2022-07-20 JP JP2024503613A patent/JP2024527424A/ja active Pending
- 2022-07-20 AU AU2022315058A patent/AU2022315058A1/en active Pending
- 2022-07-20 US US18/580,986 patent/US20250092016A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PY2261702A (es) | 2023-06-14 |
| TW202321210A (zh) | 2023-06-01 |
| KR20240038996A (ko) | 2024-03-26 |
| US20250092016A1 (en) | 2025-03-20 |
| UY39863A (es) | 2023-02-28 |
| EP4373814A1 (en) | 2024-05-29 |
| AU2022315058A1 (en) | 2024-02-08 |
| CA3226758A1 (en) | 2023-01-26 |
| WO2023002409A1 (en) | 2023-01-26 |
| JP2024527424A (ja) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000986A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. | |
| SA522433087B1 (ar) | Sos1 مثبطات | |
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| JOP20200278B1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| MX2021005012A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr. | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| CL2008001782A1 (es) | Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion. | |
| MX2018013387A (es) | Inhibidores de la arginasa y sus aplicaciones terapeuticas. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| MX2024015455A (es) | Sales de inhibidores de homologo 1 del hijo de sevenless (sos1) | |
| CR20210103A (es) | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 | |
| MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. | |
| CL2022002148A1 (es) | Inhibidores heterocíclicos de pad4 | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| CL2021002176A1 (es) | Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040) | |
| MX2023013577A (es) | Composiciones de bismuto-tiol y metodos de uso. | |
| MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| PE20200600A1 (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc | |
| BR112022023187A2 (pt) | Compostos para o tratamento da sars | |
| JOP20220355A1 (ar) | مثبطات rip1k | |
| MX2024014262A (es) | Inhibidores de parg |